Submission dates
Submitted by Anonymous (not verified) on 15 July 2025 - 13:03
Submission dates
Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 15 July 2025 - 9:09
Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 18, Status: Authorised
Agenda of the COMP meeting 15-17 July 2025
Submitted by Anonymous (not verified) on 15 July 2025 - 8:50
Agenda of the COMP meeting 15-17 July 2025
Expected publication dates of PRAC recommendations on safety signals
Submitted by Anonymous (not verified) on 15 July 2025 - 8:45
Expected publication dates of PRAC recommendations on safety signals
Agenda of the CVMP meeting 15-17 July 2025
Submitted by Anonymous (not verified) on 15 July 2025 - 8:30
Agenda of the CVMP meeting 15-17 July 2025
Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 27, Status: Authorised
Submitted by Anonymous (not verified) on 15 July 2025 - 2:32
Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 27, Status: Authorised
Human medicines European public assessment report (EPAR): Sunlenca, lenacapavir, Date of authorisation: 17/08/2022, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 14 July 2025 - 17:33
Human medicines European public assessment report (EPAR): Sunlenca, lenacapavir, Date of authorisation: 17/08/2022, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 14 July 2025 - 17:08
Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Pomalidomide Krka, pomalidomide, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 14 July 2025 - 16:42
Human medicines European public assessment report (EPAR): Pomalidomide Krka, pomalidomide, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised
EMA Information Day on submission predictability of initial marketing authorisation December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 December 2025, 13:30 (CET) to 3 December 2025, 17:30 (CET)
Submitted by Anonymous (not verified) on 14 July 2025 - 16:19
EMA Information Day on submission predictability of initial marketing authorisation December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 December 2025, 13:30 (CET) to 3 December 2025, 17:30 (CET)